Here’s a groundbreaking revelation that could change the way we approach extensive-stage small cell lung cancer (ES-SCLC): Adding consolidative thoracic radiotherapy (cTRT) after initial chemoimmunotherapy might significantly extend survival rates. But here’s where it gets controversial—while the data looks promising, not all patients may benefit equally, and the side effects, though rare, raise questions about its universal application. Let’s dive into the details.
A recent retrospective analysis has shed light on the potential of cTRT as a game-changer for ES-SCLC patients. Researchers examined data from 100 patients who underwent first-line treatment with platinum-based chemotherapy combined with immunotherapy. Based on their response to this systemic therapy, some patients were recommended to receive cTRT, creating distinct treatment cohorts for comparison. The study’s primary focus was on overall survival (OS) and progression-free survival (PFS)—two critical metrics in cancer treatment. To ensure robust findings, univariate and multivariate analyses were employed to pinpoint factors influencing OS, while the Fine-Gray competing risks model was used to assess the likelihood of locoregional progression.
The results? Patients who received cTRT saw a median OS of 26 months, compared to just 17 months for those who didn’t (P = .006). Similarly, median PFS was 10 months with cTRT versus 6 months without (P = .005). Multivariate analysis crowned cTRT as the sole independent factor linked to improved OS, with a hazard ratio of 0.48 (P = .04). And this is the part most people miss—the 1-year cumulative incidence of locoregional progression was nearly halved in the cTRT group (22.3%) compared to those without it (55.4%, P <.001). Side effects were manageable, with only 3 patients experiencing grade 3 radiation esophagitis and 5 reporting grade 1/2 radiation pneumonitis.
The study’s authors cautiously conclude that cTRT “offers potential advantages for ES-SCLC patients responding well to initial chemoimmunotherapy.” But here’s the thought-provoking question: Should cTRT become the standard of care for all ES-SCLC patients, or should its use be tailored based on individual response and risk factors? Share your thoughts in the comments—this debate is far from over.
Source:
Zhang C, Wang W, Bi N, et al. Efficacy and safety of consolidative thoracic radiotherapy for extensive-stage small cell lung cancer in the era of immunotherapy: A real-world study. Lung Cancer. Published online September 17, 2025. doi:10.1016/j.lungcan.2025.108758
Disclaimer: The views expressed are those of the author(s) and/or participants and do not necessarily reflect the opinions, policies, or positions of Oncology Learning Network or HMP Global, their employees, or affiliates. © 2025 HMP Global. All Rights Reserved.
